Small Pharma—“Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, & Uses”
“an alternative method for the synthesis of DMT and DMT-type compounds...which avoids the use of problematic oxalyl chloride whilst producing high-purity compounds”
Ixtlan Bioscience—“Psilocybin Treatment of Alzheimer’s Disease & Brain Pathologies”
Ixtlan AD Kit—“unique assembly of tools” to treat “a variety of brain pathologies by microdosing of encapsulated 5HT2A receptor agonists, specifically psilocybin”
What happens when two companies’ patents both cover the same drug?
Reunion Neuroscience’s lead RE104 = isoprocin glutarate, a prodrug of 4-OH-DiPT
Reunion $REUN has a granted patent claiming it
Today, Mindset Pharma $MSET received a notice of allowance on claims to it too
1/7
Field Trip $FTRP (the original applicant) obtained its patent on RE104 (then FT-104) after first w/drawing it from issuance to ensure examiner reviewed Mindset’s apps
Mindset’s were filed first, but only published after Field Trip’s app was allowed
New patent granted—“Delivery System for Ayahuasca-Like Substances”
Claims DMT vapes, 5-MeO-DMT vapes, & 2C-B vapes
These claims can be immediately enforced
1/6
The patent claims:
“A device for the delivery of a substance comprising:
a chamber comprising at least one vaporizable formulation wherein the vaporizable formulation comprises the substance and wherein the substance comprises one or more of”
DMT, 5-MeO-DMT, or 2C-B
2/6
The application was first filed as a provisional in July 2020
Did DMT vape pens exist in the prior art before the priority date?
This @doubleblindmag article was first published on Feb. 5, 2020: